ArticleOncoimmunology2015
Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis.
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Unveiling the sensing potential of innate lymphoid cells.Communications biology · 2026Review
- Toll-like receptors: versatile players in tumor.Frontiers in immunology · 2026Review
- Toll-like receptor 3 activation enhances antitumor immune response in lung adenocarcinoma through NF-κB signaling pathway.Frontiers in immunology · 2025Article
- Can the Analysis of Toll-like Receptors (TLR) on NK and NKT-like Cells Improve Gastric Cancer Diagnostics and Treatment?Cancers · 2024Article
- TLR Agonists Modify NK Cell Activation and Increase Its Cytotoxicity in Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2024Article
- Harnessing innate immune pathways for therapeutic advancement in cancer.Signal transduction and targeted therapy · 2024Review
- Review
- Implications of a 'Third Signal' in NK Cells.Cells · 2021Review
- EO771, is it a well-characterized cell line for mouse mammary cancer model? Limit and uncertainty.Cancer medicine · 2020Review
- Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.Signal transduction and targeted therapy · 2020Review
- Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2020Article
- Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.Journal of immunology research · 2020Review
- Preconditioning human natural killer cells with chorionic villous mesenchymal stem cells stimulates their expression of inflammatory and anti-tumor molecules.Stem cell research & therapy · 2019Article
- Natural Killer Cells in the Lungs.Frontiers in immunology · 2019Review
- Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.Frontiers in immunology · 2019Review
- Immune regulation of metastasis: mechanistic insights and therapeutic opportunities.Disease models & mechanisms · 2018Review
- Characterization of the interaction between human decidua parietalis mesenchymal stem/stromal cells and natural killer cells.Stem cell research & therapy · 2018Article
- A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation.PloS one · 2018Article
- Targeting natural killer cells in cancer immunotherapy.Nature immunology · 2016Review
- Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Toll-like receptor 3 (TLR3) agonist poly(I:C) is a promising adjuvant for cancer vaccines due to its induction of potent antitumor responses occurring primarily through the activation of dendritic cells (DCs) and natural killer (NK) cells. However, little is known about the role of TLR3 sensing of endogenous ligands in innate tumor immunosurveillance. Here, we investigated whether TLR3 could modulate immune responses and facilitate tumor control without administration of an agonist. We observed only limited impact of TLR3 deficiency on spontaneous carcinogenesis and primary growth of B16F10, E0771 or MC38 tumors when injected subcutaneously to mice. Nevertheless, TLR3 was observed to limit experimental B16F10 lung metastasis, an immunologic constraint dependent on both IFNγ secretion and NK cells. Interestingly, we observed that NK cells derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.